Heparin-based nanoparticles.

The combination of nanoparticles and biological molecules is of intense interest because of the synergistic properties offered by such newly synthesized composites. Heparin (HP), conjugated to nanomaterials, has recently been investigated for its chemical and biological properties. HP has a number of biological activities that can be enhanced when composited with nanoparticles. In addition, HP improves the biocompatibility of nanoparticles improving their performance in various biological applications. A variety of recent research combines HP and nanomaterials for a myriad of applications. HP has been conjugated to the surface of the nanoparticles, such as magnetic and metallic nanoparticles, or biodegradable and nondegradable synthetic polymers. HP has also been incorporated into the nanoparticles. There are numerous possibilities for material composites and chemistries that incorporate HP. This opens the door for novel applications ranging from improving anticoagulant activity, for anticancer and antitumor therapy, to tissue engineering and biosensors. This review examines the different possibilities of HP-based nanoparticle composites and their medicinal or biological applications.

[1]  E. Manias.  Nanocomposites: stiffer by design. , 2007, Nature materials.

[2]  Kwangmeyung Kim,et al.  Heparin/poly(l-lysine) nanoparticle-coated polymeric microspheres for stem-cell therapy. , 2007, Journal of the American Chemical Society.

[3]  J. Weiler,et al.  Heparin and modified heparin inhibit complement activation in vivo. , 1992, Journal of immunology.

[4]  G. Hadjipanayis,et al.  Development of heparin-coated magnetic nanoparticles for targeted drug delivery applications , 2009 .

[5]  W. D. de Heer,et al.  Carbon Nanotubes--the Route Toward Applications , 2002, Science.

[6]  J. S. Park,et al.  PLGA microsphere construct coated with TGF-beta 3 loaded nanoparticles for neocartilage formation. , 2008, Biomacromolecules.

[7]  C. Rider,et al.  Heparin specifically inhibits binding of V3 loop antibodies to HIV‐1 gp120, an effect potentiated by CD4 binding , 1994, AIDS.

[8]  M. Salmivirta,et al.  Selectively Desulfated Heparin Inhibits Fibroblast Growth Factor-induced Mitogenicity and Angiogenesis* , 2000, The Journal of Biological Chemistry.

[9]  J. J. Sayen,et al.  Heparin for oral use: preliminary studies. , 1993, Transactions of the American Clinical and Climatological Association.

[10]  T. Okano,et al.  Development of the polymer micelle carrier system for doxorubicin. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Robert J. Linhardt,et al.  Heparin—Protein Interactions , 2002 .

[12]  V. Nielsen.  The Detection of Changes in Heparin Activity in the Rabbit: A Comparison of Anti-Xa Activity, Thrombelastography®, Activated Partial Thromboplastin Time, and Activated Coagulation Time , 2002, Anesthesia and analgesia.

[13]  T. Lecompte,et al.  In Vitro and In Vivo Evaluation of Oral Heparin–Loaded Polymeric Nanoparticles in Rabbits , 2002, Circulation.

[14]  S. Szabó,et al.  A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. , 1985, Science.

[15]  Yi-Jen Chen,et al.  Development of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti-Helicobacter pylori therapy. , 2009, Biomaterials.

[16]  Y. Byun,et al.  Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[17]  C. Passirani,et al.  Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). , 1998, Pharmaceutical research.

[18]  Yu Suk Choi,et al.  Adipogenic differentiation of adipose tissue derived adult stem cells in nude mouse. , 2006, Biochemical and biophysical research communications.

[19]  P. Benya,et al.  Dedifferentiated chondrocytes reexpress the differentiated collagen phenotype when cultured in agarose gels , 1982, Cell.

[20]  Ick Chan Kwon,et al.  Preparation and characterization of self-assembled nanoparticles of heparin-deoxycholic acid conjugates. , 2004, Langmuir : the ACS journal of surfaces and colloids.

[21]  A. Lamprecht,et al.  Low molecular weight heparin nanoparticles: mucoadhesion and behaviour in Caco-2 cells , 2006 .

[22]  S. Mousa,et al.  Blood compatible carbon nanotubes--nano-based neoproteoglycans. , 2006, Langmuir : the ACS journal of surfaces and colloids.

[23]  S. Jimenez,et al.  Regulation of type-II collagen gene expression during human chondrocyte de-differentiation and recovery of chondrocyte-specific phenotype in culture involves Sry-type high-mobility-group box (SOX) transcription factors. , 2001, The Biochemical journal.

[24]  A. Dal Pozzo,et al.  New heparin complexes active by intestinal absorption: I-multiple ion pairs with basic organic compounds. , 1989, Thrombosis research.

[25]  Wei Wang,et al.  Advances toward bioapplications of carbon nanotubes , 2004 .

[26]  T. Olivecrona,et al.  Interaction of size-fractionated heparins with lipoprotein lipase and hepatic lipase in the rat. , 1992, The Biochemical journal.

[27]  C. Rider,et al.  Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor, CD4. , 1998, Glycobiology.

[28]  J. Weiler,et al.  Small heparin fragments regulate the amplification pathway of complement. , 1985, Immunopharmacology.

[29]  J. Saliba,et al.  Heparin in the treatment of burns: a review. , 2001, Burns : journal of the International Society for Burn Injuries.

[30]  Ya-nan Guo,et al.  Preparation and Characterization of Heparin‐Stabilized Gold Nanoparticles , 2008 .

[31]  Yu Suk Choi,et al.  Adipose tissue engineering using mesenchymal stem cells attached to injectable PLGA spheres. , 2005, Biomaterials.

[32]  P. Couvreur,et al.  A new generation of polymer nanoparticles for drug delivery. , 2010, Cellular and molecular biology.

[33]  Sung-Min Choi,et al.  Thermally reversible pluronic/heparin nanocapsules exhibiting 1000-fold volume transition. , 2006, Langmuir : the ACS journal of surfaces and colloids.

[34]  J. Bonaventure,et al.  Reexpression of cartilage-specific genes by dedifferentiated human articular chondrocytes cultured in alginate beads. , 1994, Experimental cell research.

[35]  T. Park,et al.  Synthesis, characterization, and intracellular delivery of reducible heparin nanogels for apoptotic cell death. , 2008, Biomaterials.

[36]  R. Thompson,et al.  Effects of heparin on wound healing. , 1972, Surgery, gynecology & obstetrics.

[37]  B. Ratner.  Blood compatibility — a perspective , 2000, Journal of biomaterials science. Polymer edition.

[38]  K. Kataoka,et al.  Block copolymer micelles for drug delivery: design, characterization and biological significance. , 2001, Advanced drug delivery reviews.

[39]  R. Linhardt,et al.  Heparin, Heparinoids and Heparin Oligosaccharides: Structure and Biological Activities , 1990 .

[40]  L. Nie,et al.  An Amperometric Glucose Biosensor Based on Glucose Oxidase Immobilized in Electropolymerized Poly(o-aminophenol) and Carbon Nanotubes Composite Film on a Gold Electrode , 2005, Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.

[41]  Sergio A. Jimenez,et al.  Regulation of type-II collagen gene expression during human chondrocyte de-differentiation and recovery of chondrocyte-specific phenotype in culture involves Sry-type high-mobility-group box (SOX) transcription factors. , 2001 .

[42]  P. Couvreur,et al.  Novel Polysaccharide-Decorated Poly(Isobutyl Cyanoacrylate) Nanoparticles , 2003, Pharmaceutical Research.

[43]  P. Couvreur,et al.  Polymeric Micro- and Nanoparticles as Drug Carriers , 2001 .

[44]  G. Chow,et al.  Carboxyl group (–CO2H) functionalized ferrimagnetic iron oxide nanoparticles for potential bio-applications , 2004 .

[45]  L. Kjellén,et al.  Proteoglycans: structures and interactions. , 1991, Annual review of biochemistry.

[46]  Xiurong Yang,et al.  Synthesis of polysaccharide-stabilized gold and silver nanoparticles: a green method. , 2004, Carbohydrate research.

[47]  C. Passirani,et al.  Development of a New Class of Nanoparticles which Avoid Phagocytosis by Inhibiting Complement Activation , 1998 .

[48]  D. Rabenstein.  Heparin and heparan sulfate: structure and function. , 2002, Natural product reports.

[49]  P. Ajayan.  Nanotubes from Carbon. , 1999, Chemical reviews.

[50]  M. McBurney,et al.  Poly(D,L lactic-co-glycolic acid) microspheres as biodegradable microcarriers for pluripotent stem cells. , 2004, Biomaterials.

[51]  M. Salmivirta,et al.  Heparan sulfate : a piece of information , 2004 .

[52]  P. Ajayan,et al.  Synthesis of gold and silver nanoparticles stabilized with glycosaminoglycans having distinctive biological activities. , 2009, Biomacromolecules.

[53]  Christine Vauthier,et al.  Heparin coated poly(alkylcyanoacrylate) nanoparticles coupled to hemoglobin: a new oxygen carrier. , 2004, Biomaterials.

[54]  Zong-hua Liu,et al.  Heparin/chitosan nanoparticle carriers prepared by polyelectrolyte complexation. , 2007, Journal of biomedical materials research. Part A.

[55]  H. Hashimoto,et al.  Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung , 2002, British Journal of Cancer.

[56]  S. Mousa,et al.  Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin , 2006, Thrombosis and Haemostasis.

[57]  R. Langer,et al.  Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. , 1983, Science.

[58]  R. Linhardt.  2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity. , 2003, Journal of medicinal chemistry.

[59]  M. Tatematsu,et al.  Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. , 2004, Cancer letters.